Amgen (AMGN) Change in Receivables (2009 - 2026)

Amgen's Change in Receivables history runs 18 years deep, the most recent figure standing at -$413.0 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 131.57% year-over-year to -$413.0 million; the TTM figure through Mar 2026 stood at $955.0 million (down 29.42% YoY), while the FY2025 annual figure was $2.7 billion, up 706.8% from the prior year.
• Change in Receivables was -$413.0 million for Q1 2026 at Amgen, down from $1.1 billion in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $1.3 billion in Q1 2025 to a low of -$486.0 million in Q1 2024.
• Historically, Change in Receivables has averaged $210.8 million across 5 years, with a median of $180.0 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Change in Receivables jumped 451.79% in 2022, then plunged 437.5% in 2024.
• A 5-year view of Change in Receivables shows it stood at $180.0 million in 2022, then soared by 140.56% to $433.0 million in 2023, then plunged by 209.24% to -$473.0 million in 2024, then surged by 327.27% to $1.1 billion in 2025, then sank by 138.42% to -$413.0 million in 2026.
• The last three Change in Receivables figures came in at -$413.0 million (Q1 2026), $1.1 billion (Q4 2025), and -$222.0 million (Q3 2025), per Business Quant data.